Neobe Therapeutics

📍 London, United Kingdom🗓 Founded 2021👥 13 employees💰 Last funded Dec 2023
Biotechnology Research🌐 neobetherapeutics.com
Website LinkedIn
At Neobe Therapeutics we are engineering tumour-colonizing bacteria that will disrupt tumour micro environment barriers and enable immunotherapies in patients with immune-excluded tumours. Only around 20% of patients with solid tumors are estimated to currently benefit from immunotherapies. Multiple factors contribute to this low level of efficacy. Chief among them is the existence of an immunosuppressive microenvironment that leads to the generation of immune "cold" tumours. At Neobe we are harnessing the synthetic biology toolkit to engineer tumour-colonizing bacteria that locally disrupt this microenvironment. By acting locally within the tumor, these products avoid systemic toxicities while increasing drug efficacy. Disrupting these barriers and increasing immune cell infiltration in "cold" tumours will enable the success of immunotherapies in current non-responders.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Neobe Therapeutics?
Neobe Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Neobe Therapeutics last raise funding?
The most recent investment in Neobe Therapeutics recorded on gritt.io was in December 2023.
When was Neobe Therapeutics founded?
Neobe Therapeutics was founded in 2021.
What industry is Neobe Therapeutics in?
Neobe Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Neobe Therapeutics based?
Neobe Therapeutics is headquartered in London, United Kingdom.